FindTrial
Sign In

Expanded Access Use of Ladiratuzumab Vedotin in Advanced Solid Tumors

Status
AVAILABLE
Phases
Unknown
Study type
Expanded Access
Source
ClinicalTrials.gov
Registry ID
NCT06362590
Enrollment
Unknown
Registered
2024-04-12
Start date
Unknown
Completion date
Unknown
Last updated
2026-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

The purpose of this study is to provide the option of Ladiratuzumab Vedotin treatment to eligible patients in studies SGNLVA-005.

Interventions

DRUGladiratuzumab vedotin

Sponsors

Seagen Inc.
Lead SponsorINDUSTRY

Eligibility

Inclusion criteria

\-

Exclusion criteria

\-

Contacts

CONTACTSeagen Trial Information Support
clinicaltrials@seagen.com866-333-7436

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 9, 2026